Gregg Stone cast doubt on its reliability in trials, while David Cohen said QoL matters to patients and should be measured.

Merging interventional and AHFTC training programs would be a boon for patients and the HF subspecialty, experts argue.

Demystifying the AED, and training a generation of kids in their use, is key to prevent “catastrophic” sudden deaths in young ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

The complications portend a rise in the arrhythmia, and also in mortality, with an average time to event of 7 years.

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Sreek Vemulapalli and Roseann White explain the statistical challenges that can arise while collecting longer-term follow-up ...

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.